Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATAO maintenance letrozole trial in epithelial ovarian cancer
2024-511219-78-00Phase 3Authorised
- Sponsor
- Swiss GO Trial Group
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Letrozole maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-Free Survival. Planned start Feb 2023; status: authorised.
02
Drugs
letrozole
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-511219-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511219-78-00.